期刊文献+

应用流式细胞术评估多发性骨髓瘤预后的研究进展 被引量:7

Recent Advances on the Prognostic Value of Immunophenotyping in Multiple Myeloma by Flow Cytometry——Review
下载PDF
导出
摘要 流式细胞术在多发性骨髓瘤方面的临床应用很为广泛,例如可以应用于与反应性浆细胞增多的区别诊断、疾病进展的监测、疾病预后的评估、微小残留病的监测等等。以流式细胞术为基础的免疫表型克隆分析,促进了更严格的诊断和随访技术的发展。本综述主要是介绍最新的骨髓瘤的恶性浆细胞的免疫表型、最广泛的抗原(如CD19,CD33,CD28,CD45,CD56及CD117)在正常的和恶性的浆细胞的表达的差别。本综述还着重介绍了恶性浆细胞表型和染色体异常之间的相关性,明确多发性骨髓瘤的预后因素。 Clinical application of flow cytometry in multiple myeloma (MM) can be found in various dimensions, such as in differential diagnosis of malignant plasma cell disorder from reactive plasmacytosis, identification of the progression risk in MM, and in the detection of minimal residual disease. Flow cytometry-based clonality assessment with immuno-phenotyping encourages and enables the most stringent method of diagnosis and follow-up. The objective of this review is to summarize the recent information of the malignant plasma cell phenotypic profile of MM. The most comprehensive antigens, such as CD19, CD27, CD28, CIM5, CD56 and CDll7, play a significant role in the characterization of normal and malignant plasma cells. This review also focuses on the association of malignant phenotypic markers with chromosomal aberrations that identify the specific prognostic factors in MM.
出处 《中国实验血液学杂志》 CAS CSCD 北大核心 2014年第4期1178-1182,共5页 Journal of Experimental Hematology
关键词 流式细胞术 免疫表型 多发性骨髓瘤 multiple myeloma immunophenotyping flow cytometry
  • 相关文献

参考文献45

  • 1San Miguel JF,Gutierrez NC,Mateo G,et al.Conventional diagnostics in multiple myeloma.Eur J Cancer,2006;42(11):1510-1519.
  • 2Raja KR,Kovarova L,Hajek R.Review of phenotypic markers used in flow cytometric analysis of MGUS and MM,and applicability of flow cytometry in other plasma cell disorders.Br J Haematol,2010;149(3):334-351.
  • 3Rawstron AC,Davies FE,DasGupta R,et al.Flow cytometric disease monitoring in multiple myeloma:the relationship between normal and neoplastic plasma cells predicts outcome after transplantation.Blood,2002;100(9):3095-3100.
  • 4Perez-Andres M,Almeida J,Martin-Ayuso M,et al.Clonal plasma cells from monoclonal gammopathy of undetermined significance,multiple myeloma and plasma cell leukemia show different expression profiles of molecules involved in the interaction with the immunological bone marrow microenvironment.Leukemia,2005;19(3):449-455.
  • 5Moreau P,Robillard N,Avet-Loiseau H,et al.Patients with CD45negative multiple myeloma receiving high-dose therapy have it shorter survival than those with CD45 positive multiple myeloma.Haematologica,2004;89(5):547-551.
  • 6Mateo G,Montalbán MA,Vidriales MB,et al.Prognostic value of immunophenotyping in multiple myeloma:a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy.J Clin Oncol,2008;26(16):2737-2744.
  • 7Bahlis NJ,King AM,Kolonias D,et al.CD28-mediated regulation of multiple myeloma cell proliferation and survival.Blood,2007;109(11):5002-5010.
  • 8Rawstron AC,Orfao A,Beksac M,et al.Report of the European Myeloma Network on multiparametric flow cytometry in multiple myeloma and related disorders.Haematologica,2008;93(3):431-438.
  • 9Paiva B,Vidriales MB,Pérez JJ,et al.Multiparameter flow cytometry quantification of bone marrow plasma cells at diagnosis provides more prognostic information than morphological assessment in myeloma patients.Haematologica,2009;94(11):1599-1602.
  • 10Smock KJ,Perkins SL,Bahler DW.Quantitation of plasma cells in bone marrow aspirates by flow cytometric analysis compared with morphologic assessment.Arch Pathol Lab Med,2007;131(6):951-955.

二级参考文献34

  • 1庄俊玲,汪玄,武永吉.CD138/Syndecan-1在多发性骨髓瘤免疫表型中的意义[J].中国实验血液学杂志,2005,13(6):1023-1027. 被引量:10
  • 2Kara IO, Sahin B, Paydas S, et al. Flow cytometric evaluation of bone marrow plasma cells using CD19, CD45, CD56, CD38, and CD138 and correlation with bone marrow infiltration ratio in multiple myeloma patients. Saudi Med J, 2004; 25( 11 ) : 1587 - 1592.
  • 3Braylan RC, Orfao A, Borowitz MJ, et al. Optimal number o4 reagents required to evaluate hematolymphoid neoplasia: results of an international consensus meeting. Cytometry, 2001 ;46 ( 1 ) :23 27.
  • 4Lin P, Owens R, Tricot G, et al. Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma. Am J Clin Pathol, 2004, 121 (4): 482-488.
  • 5Sun RX, Lu ZY, Wijdenes J, et al. Large scale and clinical grade purification of syndecan-1 ^+ malignant plasma cells. J lmmunol Methods, 1997 ;205 ( 1 ) :73 - 79.
  • 6Matsui W, Huff CA, Wang QJ, et al. Characterization of clonogenic multiple myeloma cells. Blood, 2004 ; 103 (6) : 2332 - 2336.
  • 7Aref S, Goda T, El-Sherbiny M. Syndecan-I in multiple myeloma: relationship to conventional prognostic factors. Hematology, 2003 ; 8(4) :221 -228.
  • 8Yang Y, Yaccoby S, Liu W. Soluble syndecan-1 promotes growth of myeloma tumors in vivo. Blood, 2002 ;100(2) :610 -617.
  • 9Bashey A, Cantwell MJ, Kipps TJ, et al. Adenovirus transduction to effect CD40 signalling improves the immune stimulatory activity of myeloma cells. Br J Haematol, 2002 ; 118 (2) :506 - 513.
  • 10Mateo G, Castellanos M, Rasillo A, et al. Genetic abnormalities and patterns of antigenic expression in multiple myeloma. Clin Cancer Res, 2005 ; 11 (10) : 3661 - 3667.

共引文献21

同被引文献37

引证文献7

二级引证文献25

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部